Keywordsibrutinib, lenalidomide, maximum tolerated doses, refractory non-GCB DLBCL, relapsed
Principal InvestigatorNam H Dang, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.